PTEN and prostate carcinoma: Sequencing of primary prostate carcinomas and castration resistant prostate carcinomas have identified recurrent molecular alterations, including ETS family transcription factor fusions; mutations in SPOP, FOXA1, and TP53; PTEN loss; and AR amplification [2, 3].